NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Coya Therapeutics, Inc. (COYA) Stock Analysis

Coya Therapeutics, Inc. (COYA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

COYA

$4.76

+$0.21 (+4.62%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare COYA with… →

COYA Key Statistics

As of Sep 4, 2026
Trading
Open
$4.54
Previous Close
$4.55
Day's Range
4.52–4.77
52-Week Range
3.71–7.75
Volume
75.60K
Valuation
Market Cap
$111.66M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.92
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.07
Financials (FY)
Revenue (FY)
$7.95M+123.57%
Net Income (FY)
−$21.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
−270.22%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
23.46M
1-Year Return
−25.39%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
184.51K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

COYA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.93%
2025+1.22%
2024−22.67%
2023+56.40%
2022 (partial year)+3.68%

As of September 4, 2026.

COYA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.95M−$21.23M−267.1%
2024$3.55M−$14.88M−418.7%
2023$6.00M−$7.99M−133.1%
2022$0.00−$12.24M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.95M—−$22.56M−$21.23M−267.1%
2024$3.55M—−$17.25M−$14.88M−418.7%
2023$6.00M—−$7.90M−$7.99M−133.1%
2022$0.00—−$9.81M−$12.24M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

COYA Valuation vs Biotechnology Median

Median of 656 stocks
MetricCOYABiotechnology medianvs median
P/S ratio13.9215.269% below
Profit margin−270.22%0.00%270.2 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Coya Therapeutics, Inc. (COYA) carries a market capitalisation of $111.66M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 8 employees.

Over the past 52 weeks the price has ranged from $3.71 to $7.75. The most recent close on file for COYA is $4.76, dated September 4, 2026. That is +$0.21 (+4.62%) against the previous close. The latest close sits 28.3% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $7.95M. That is +123.57% against the prior fiscal year, when revenue was $3.55M. The same year closed with a net loss of $21.23M. Profit margin runs at −270.22%. That is 270.2 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −1.07.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $7.95M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 13.92 times revenue. On price-to-sales that is 8.78% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −25.39%. Across 3 years the annualized return works out at +10.27%. Daily returns over the trailing 3 years annualize to a volatility of 71.82%.

Growth & Income

The record shows no dividend for COYA.

2026 is still running; the price is −17.93% year to date. Across the complete calendar years on file, 2023 returned +56.40% and 2024 returned −22.67%. Of the 3 complete calendar years on file, 2 finished higher.

Peer Comparison

Coya Therapeutics, Inc. (COYA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Coya Therapeutics, Inc. COYA $111.66M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Coya Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.

Visit website →